Randomized Trial Comparing Minocycline-EDTA-Ethanol Lock to Standard-of-Care Antibiotic Lock for Management of Central Line–Associated Bloodstream Infection

Clicks: 25
ID: 332620
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #245 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Central line-associated bloodstream infections (CLABSI) cause substantial morbidity and mortality. Management often requires removing the infected central venous catheter (CVC) and inserting a new one. Effective catheter-salvage strategies are needed. METHODS: An international, multicenter, prospective, randomized superiority trial at 34 centers in the United States, Puerto Rico, and India enrolled patients aged ≥12 years with a long-term central venous catheter (CVC) in place for ≥5 days and CLABSI. Participants were randomized 1:1 to receive systemic antibiotics plus minocycline-EDTA-ethanol lock therapy (MLT) or standard-of-care antibiotic lock therapy (SOC-ALT) for 7 to 14 days. The primary endpoint was median time to catheter failure, defined as clinical failure (death, infection-related catheter removal, worsening symptoms) or microbial failure (persistent/recurrent infection or new deep-seated infection attributable to the index CLABSI). RESULTS: From 2018-2024, 241 patients were randomized; 228 received lock therapy. Catheter retention was higher with MLT than SOC-ALT (57% vs 38%; P = 0.0025). Median time to catheter failure was longer with MLT in both intention-to-treat (not estimable vs 33 days, HR 0.53, P = 0.0006) and modified intention-to-treat populations (not estimable vs 35 days, HR 0.50, P = 0.0005). Clinical catheter failure (13% vs 28%; P = 0.006) and microbiological failure (5% vs 15%; P = 0.012) were lower with MLT. Adverse events, serious adverse events, and mortality were similar between groups, with no drug-related serious adverse events. CONCLUSIONS: MLT was superior to SOC-ALT in salvaging long-term CVCs in CLABSI and was well tolerated, addressing an unmet need in CLABSI management.
Reference Key
openalex_W7222657814 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anne‐Marie Chaftari, Vijay Rathore, Ray Y Hachem, Toan T. Huynh, Paul Cook, Onix J. Cantres-Fonseca, Mayur S. Ramesh, Princy N. Kumar, Mark E. Rupp, Leonard A. Mermel, Myron S Czuczman, Alan S. Lader, Issam I. Raad
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag660
URL
https://doi.org/10.1093/cid/ciag660
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.